Logo

Osmetech Licenses Warfarin-Dosing SNP From Marshfield Clinic

Nov 02, 2007
NEW YORK (GenomeWeb News) - Osmetech said today it has exclusively licensed a molecular biomarker from Marshfield Clinic, a clinical and research facility in western Wisconsin, that it plans develop into a genetic test for determining appropriate warfarin doses.  
 
Osmetech plans to develop, manufacture, and sell a genetic test based on the biomarker. Osmetech CEO James White said the biomarker will be used on the company’s XT-8 platform.
 
"We are excited to add this new SNP to our warfarin product which is due to be submitted later this year to the US Food and Drug Administration,” White said in a statement. “The marker provides additional information to improve the dosage accuracy over any other product on the market."
 
Osmetech said it plans to market the product in the first half of 2008.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.